SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
复制标题
DOI：
10.1093/infdis/jiac332
复制
发表时间：
2022-12-28
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
自出现严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）以来，人类通过感染不同变体和/或接种疫苗接触了不同的SARS-CoV-2抗原。因此，人群免疫是高度异质性的，但这种异质性对抗体介导应答的有效性和广度的影响尚不清楚。我们测量了抗体介导的对SARS-CoV-2Wuhan、SARS-CoV-2α、SARS-CoV-2δ和SARS-CoV-2ο假病毒的中和反应，使用不同免疫史患者的血清，包括初诊、接种疫苗、感染SARS-CoV-2Wuhan、SARS-CoV-2α或SARS-CoV-2δ以及接种疫苗/感染者。我们发现抗体介导应答的广度和效力受到暴露的数量、变异和性质（感染或疫苗接种）的影响，并且通过疫苗接种和自然暴露获得混合免疫的个体表现出最广泛和最有效的应答。我们的研究结果表明，宿主免疫与SARS-CoV-2进化之间的相互作用将决定SARS-CoV-2的抗原性和随后的传播动力学，对未来的疫苗设计具有重要意义。抗体介导的SARS-CoV-2应答的广度和效力受感染变异的暴露类型、暴露次数和基因型的影响。通过疫苗接种和感染获得混合免疫的患者表现出最有效的反应。
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans have been exposed to distinct SARS-CoV-2 antigens, either by infection with different variants, and/or vaccination. Population immunity is thus highly heterogeneous, but the impact of such heterogeneity on the effectiveness and breadth of the antibody-mediated response is unclear. We measured antibody-mediated neutralization responses against SARS-CoV-2Wuhan, SARS-CoV-2α, SARS-CoV-2δ, and SARS-CoV-2ο pseudoviruses using sera from patients with distinct immunological histories, including naive, vaccinated, infected with SARS-CoV-2Wuhan, SARS-CoV-2α, or SARS-CoV-2δ, and vaccinated/infected individuals. We show that the breadth and potency of the antibody-mediated response is influenced by the number, the variant, and the nature (infection or vaccination) of exposures, and that individuals with mixed immunity acquired by vaccination and natural exposure exhibit the broadest and most potent responses. Our results suggest that the interplay between host immunity and SARS-CoV-2 evolution will shape the antigenicity and subsequent transmission dynamics of SARS-CoV-2, with important implications for future vaccine design. The breadth and potency of the antibody-mediated response against SARS-CoV-2 is influenced by the exposure type, the number of exposures, and the genotype of the infecting variant. Patients with mixed immunity acquired by vaccination and infection exhibit most effective responses.
登录
查看更多内容
影响因子：
24.8
作者：
Bates TA;McBride SK;Leier HC;Guzman G;Lyski ZL;Schoen D;Winders B;Lee JY;Lee DX;Messer WB;Curlin ME;Tafesse FG
通讯作者：
Tafesse FG
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
6.4
作者：
Ibarrondo FJ;Hofmann C;Ali A;Ayoub P;Kohn DB;Yang OO
通讯作者：
Yang OO
影响因子：
64.8
作者：
Mlcochova P;Kemp SA;Dhar MS;Papa G;Meng B;Ferreira IATM;Datir R;Collier DA;Albecka A;Singh S;Pandey R;Brown J;Zhou J;Goonawardane N;Mishra S;Whittaker C;Mellan T;Marwal R;Datta M;Sengupta S;Ponnusamy K;Radhakrishnan VS;Abdullahi A;Charles O;Chattopadhyay P;Devi P;Caputo D;Peacock T;Wattal C;Goel N;Satwik A;Vaishya R;Agarwal M;Indian SARS-CoV-2 Genomics Consortium (INSACOG);Genotype to Phenotype Japan (G2P-Japan) Consortium;CITIID-NIHR BioResource COVID-19 Collaboration;Mavousian A;Lee JH;Bassi J;Silacci-Fegni C;Saliba C;Pinto D;Irie T;Yoshida I;Hamilton WL;Sato K;Bhatt S;Flaxman S;James LC;Corti D;Piccoli L;Barclay WS;Rakshit P;Agrawal A;Gupta RK
通讯作者：
Gupta RK
DOI：
10.1126/science.abn4947
发表时间：
2022-05-06
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Pulliam JRC;van Schalkwyk C;Govender N;von Gottberg A;Cohen C;Groome MJ;Dushoff J;Mlisana K;Moultrie H
通讯作者：
Moultrie H